Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.

Damiani D, Tiribelli M, Franzoni A, Michelutti A, Fabbro D, Cavallin M, Toffoletti E, Simeone E, Fanin R, Damante G.

Am J Hematol. 2013 Oct;88(10):848-52. doi: 10.1002/ajh.23516. Epub 2013 Jul 23.

2.
3.

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

4.

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).

Santamaría C, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Mateos MV, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodríguez JN, Puig N, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel J, González M.

Ann Hematol. 2010 May;89(5):453-8. doi: 10.1007/s00277-009-0864-x. Epub 2009 Nov 27.

PMID:
19943049
5.

WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.

Miglino M, Colombo N, Pica G, Grasso R, Clavio M, Bergamaschi M, Ballerini F, Ghiso A, Ghiggi C, Mitscheunig L, Beltrami G, Cagnetta A, Vignolo L, Lucchetti MV, Aquino S, Pierri I, Sessarego M, Carella AM, Gobbi M.

Leuk Lymphoma. 2011 Oct;52(10):1961-9. doi: 10.3109/10428194.2011.585673.

PMID:
21942328
6.

Prognostic implication of BAALC gene expression in adult acute myeloid leukemia.

Yahya RS, Sofan MA, Abdelmasseih HM, Saudy N, Sharaf-Eldein MA.

Clin Lab. 2013;59(5-6):621-8.

PMID:
23865362
7.

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.

Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M.

J Clin Oncol. 2011 Jul 20;29(21):2889-96. doi: 10.1200/JCO.2011.35.4894. Epub 2011 Jun 13.

PMID:
21670448
8.

Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.

Mizushima Y, Taki T, Shimada A, Yui Y, Hiraumi Y, Matsubara H, Watanabe M, Watanabe K, Kamitsuji Y, Hayashi Y, Tsukimoto I, Kobayashi R, Horibe K, Tawa A, Nakahata T, Adachi S.

Int J Hematol. 2010 Jun;91(5):831-7. doi: 10.1007/s12185-010-0585-x. Epub 2010 May 22.

PMID:
20495894
9.

Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome.

Guo X, Shi P, Chen F, Zha J, Liu B, Li R, Dong H, Zheng H, Xu B.

Blood Cells Mol Dis. 2014 Sep;53(3):144-8. doi: 10.1016/j.bcmd.2014.05.001. Epub 2014 May 20.

PMID:
24855032
10.

CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavorable acute myeloid leukemia.

Chen MH, Atenafu E, Craddock KJ, Brandwein J, Chang H.

Leuk Res. 2013 Feb;37(2):122-8. doi: 10.1016/j.leukres.2012.09.019. Epub 2012 Oct 23.

PMID:
23092917
11.

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, Caligiuri MA, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, Bloomfield CD.

Blood. 2003 Sep 1;102(5):1613-8. Epub 2003 May 15.

12.

Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia.

Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Lim JH.

Leuk Lymphoma. 2014 Jan;55(1):110-20. doi: 10.3109/10428194.2013.800869. Epub 2013 Jun 12.

PMID:
23647058
13.

BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.

Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Lim JH.

Eur J Haematol. 2013 Aug;91(2):112-21. doi: 10.1111/ejh.12142. Epub 2013 Jun 28.

PMID:
23672350
14.

Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia.

Najima Y, Ohashi K, Kawamura M, Onozuka Y, Yamaguchi T, Akiyama H, Sakamaki H.

Int J Hematol. 2010 May;91(4):636-45. doi: 10.1007/s12185-010-0550-8. Epub 2010 Apr 8.

PMID:
20376583
15.

DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups.

Ohgami RS, Ma L, Ren L, Weinberg OK, Seetharam M, Gotlib JR, Arber DA.

Br J Haematol. 2012 Oct;159(2):182-90. doi: 10.1111/bjh.12029. Epub 2012 Aug 28.

PMID:
22924777
16.

BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.

Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G.

J Clin Oncol. 2006 Feb 10;24(5):790-7. Epub 2006 Jan 17.

PMID:
16418499
17.

High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.

Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K, Delwel R.

J Clin Oncol. 2010 Apr 20;28(12):2101-7. doi: 10.1200/JCO.2009.26.0646. Epub 2010 Mar 22.

PMID:
20308656
18.

High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.

Heuser M, Beutel G, Krauter J, Döhner K, von Neuhoff N, Schlegelberger B, Ganser A.

Blood. 2006 Dec 1;108(12):3898-905. Epub 2006 Aug 15.

19.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 Feb 1;28(4):596-604. doi: 10.1200/JCO.2009.25.1496. Epub 2009 Dec 21.

20.

The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.

Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J.

Blood Cancer J. 2015 Oct 2;5:e352. doi: 10.1038/bcj.2015.76.

Supplemental Content

Support Center